Morgan Stanley revised its earnings projections for Sinopharm Group (01099), reducing forecasts across 2025-2030 by 1%-6%. This adjustment reflects lowered sales expectations within both medical equipment and pharmaceutical distribution segments. Concurrently, the investment bank decreased its price target from HK$23 to HK$22.5 while reaffirming an Overweight stance on the stock. The recalibration signals cautious near-term sector outlook despite continued confidence in the company's strategic positioning.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。